CHEBI:6498 - lipoxin A4

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name lipoxin A4
ChEBI ID CHEBI:6498
ChEBI ASCII Name lipoxin A4
Definition A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information eMolecules:539943, ZINC000004097074
Download Molfile XML SDF
more structures >>
Formula C20H32O5
Net Charge 0
Average Mass 352.46508
Monoisotopic Mass 352.22497
InChI InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
InChIKey IXAQOQZEOGMIQS-SSQFXEBMSA-N
SMILES CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O
Metabolite of Species Details
Homo sapiens (NCBI:txid9606) See: DOI
Roles Classification
Chemical Role(s): Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
Biological Role(s): human metabolite
Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via lipoxin )
Application(s): specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via lipoxin )
View more via ChEBI Ontology
ChEBI Ontology
Outgoing lipoxin A4 (CHEBI:6498) has role human metabolite (CHEBI:77746)
lipoxin A4 (CHEBI:6498) has role metabolite (CHEBI:25212)
lipoxin A4 (CHEBI:6498) is a hydroxy polyunsaturated fatty acid (CHEBI:140345)
lipoxin A4 (CHEBI:6498) is a lipoxin (CHEBI:6497)
lipoxin A4 (CHEBI:6498) is a long-chain fatty acid (CHEBI:15904)
lipoxin A4 (CHEBI:6498) is conjugate acid of lipoxin A4(1−) (CHEBI:67026)
Incoming 20-hydroxylipoxin A4 (CHEBI:90976) has functional parent lipoxin A4 (CHEBI:6498)
lipoxin A4(1−) (CHEBI:67026) is conjugate base of lipoxin A4 (CHEBI:6498)
IUPAC Name
(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
Synonyms Sources
(5S,6R,15S)-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid ChEBI
(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid ChEBI
(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyeicosa-7,9,11,13-tetraenoic acid ChEBI
(7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoic acid KEGG COMPOUND
5(S),6(R),15(S)-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic acid ChEBI
5S,6R,15S-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid ChEBI
5S,6R,15S-Trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid KEGG COMPOUND
5S,6R-LipoxinA4 LIPID MAPS
6R-LXA4 ChEBI
Lipoxin A4 KEGG COMPOUND
lipoxin A4 ChEBI
LXA4 KEGG COMPOUND
LXA4 ChEBI
Manual Xrefs Databases
C06314 KEGG COMPOUND
HMDB0004385 HMDB
LMFA03040001 LIPID MAPS
View more database links
Registry Number Type Source
4698639 Reaxys Registry Number Reaxys
Citations
Maldonado-Pérez D, Golightly E, Denison FC, Jabbour HN, Norman JE (2011)
A role for lipoxin A4 as anti-inflammatory and proresolution mediator in human parturition.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 25, 569-575 [PubMed:20959513]
[show Abstract]
Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T (2011)
Lipoxin A₄ inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression.
Infection and immunity 79, 1489-1497 [PubMed:21263017]
[show Abstract]
Das UN (2011)
Lipoxin A4 may function as an endogenous anti-arrhythmic molecule.
Medical hypotheses 76, 14-16 [PubMed:20833483]
[show Abstract]
Zhou M, Chen B, Sun H, Deng Z, Andersson R, Zhang Q (2011)
The protective effects of Lipoxin A4 during the early phase of severe acute pancreatitis in rats.
Scandinavian journal of gastroenterology 46, 211-219 [PubMed:20950211]
[show Abstract]
Chan MM, Moore AR (2010)
Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production.
Journal of immunology (Baltimore, Md. : 1950) 184, 6418-6426 [PubMed:20435922]
[show Abstract]
Das UN (2010)
Is lipoxins A4 a better alternative to anti-TNF-alpha antibody to prevent and treat diabetic macular edema and retinopathy?
Medical science monitor : international medical journal of experimental and clinical research 16, LE13-4 [PubMed:20802423]
Papayianni A, Serhan CN, Brady HR (1996)
Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells.
Journal of immunology (Baltimore, Md. : 1950) 156, 2264-2272 [PubMed:8690917]
[show Abstract]
Last Modified
05 March 2018